… The results of this study suggest that using biosimilar rituximab and biosimilar trastuzumab
to treat cancer patients in the real-world clinical setting is associated with acceptable safety …

… As such, real-world clinical data are collected usually without the exclusion of patients …
selected for this study: pertuzumab, trastuzumab emtansine, palbociclib and ribociclib (breast …

… trastuzumab originator to biosimilars in terms of safety and cost-saving over a period of 2 years.
Access to trastuzumab biosimilars … each biosimilar are not the same because the hospital …

… 1 (1.7%) patient with HER2-positive breast cancer discontinuing CT-P6 owing to serious
ADRs in a prospective, hospital-based, intensive safety monitoring study [Citation27] and 7/271 (…

… are approved by regulatory agencies via an independent pathway that requires extensive …
numerous biosimilars of these therapies, principally bevacizumab, rituximab, and trastuzumab. …

… treatment in a hospital-based intensive safety monitoring study for … [Citation10], while several
real-world reports in patients with RA … in real-world settings that repeated cycles of rituximab …

… up by many colleagues in hospitals, universities, regulatory … antibodies trastuzumab and
rituximab for breast cancer, … will have typically had extensive experience with managing …

… such as rituximab, bevacizumab, and trastuzumab, alongside … the real-world effectiveness
of trastuzumab biosimilars … single Portuguese oncology hospital tracked the treatment of …

… up by many colleagues in hospitals, universities, regulatory … antibodies trastuzumab and
rituximab for breast cancer, … will have typically had extensive experience with managing …

… patients within a Portuguese oncology hospital using an intensive monitoring programme. …
in the real world setting, the biosimilar rituximab and biosimilar trastuzumab to treat cancer …